NCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
Clinical Trials
39 trialsNCT01526096 2025-11-05
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
Phase 1 Completed
NCT01186224 2025-03-17
PHANTASTIC
University of Liverpool
Phase NA Completed
NCT04177810 2024-02-23
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03406091 2024-02-20
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients
Fondazione EMN Italy Onlus
Completed
NCT04552743 2022-09-10
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
Stanford University
Phase 2 Completed
NCT02703779 2021-06-18
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
University of Kansas Medical Center
Phase 2 Completed
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02416908 2020-03-13
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT01146834 2019-12-27
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
Weill Medical College of Cornell University
Phase 3 Completed
NCT02179970 2019-07-23
CAM-PLEX
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT01319864 2018-09-07
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
Seattle Children's Hospital
Phase 1 Completed
NCT01352650 2018-07-02
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Weill Medical College of Cornell University
Phase 1 Completed
NCT01373229 2018-02-05
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Duke University
Phase 1 Completed
NCT01097057 2018-01-23
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01403896 2017-08-02
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Nova Scotia Health Authority
Phase 2 Completed
NCT01339572 2017-08-01
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
University of Florida
Phase 2 Completed
NCT02098109 2017-07-18
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT00241358 2017-06-06
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
Phase 1/2 Completed
NCT01158118 2017-06-05
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Washington University School of Medicine
Phase 2 Completed
NCT00914849 2017-05-17
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Washington University School of Medicine
Phase 2 Completed
NCT01435343 2017-04-25
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00906945 2017-04-04
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Washington University School of Medicine
Phase 1/2 Completed
NCT00943943 2017-03-29
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00733824 2017-03-09
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Washington University School of Medicine
Phase 1/2 Completed
NCT00512252 2016-12-12
AMD3100+MEC
Washington University School of Medicine
Phase 1/2 Completed
NCT00998049 2015-05-14
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Mayo Clinic
Phase 2 Completed
NCT01095757 2014-09-29
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Emory University
Phase 2 Completed
NCT01141543 2014-07-18
Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection
University Health Network, Toronto
Completed
NCT01225419 2014-07-08
MEP1
University Hospital, Clermont-Ferrand
Phase 2 Completed
NCT01236144 2014-06-11
AML18 Pilot
Cardiff University
Phase 1/2 Completed
NCT00901225 2014-05-07
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
Phase 2 Completed
NCT01220375 2014-04-17
PAV
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT01068301 2014-01-01
A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01037517 2013-10-31
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
CancerCare Manitoba
Phase 2 Completed
NCT01074060 2013-02-15
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT01700608 2012-10-04
Prospective Observational Study on Plerixafor After Chemotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed